Improved nonviral cancer suicide gene therapy using survivin promoter-driven mutant Bax

Area of Science:

• Oncology
• Gene Therapy
• Molecular Biology

Background:

• Suicide gene therapy offers a promising cancer treatment strategy.
• Current limitations include safety concerns and variable efficacy.
• Tumor-specific promoters like survivin enhance targeting, but often require boosted gene activity.

Purpose of the Study:

• To develop a more effective and specific suicide gene therapy for cancer.
• To enhance the cytotoxic activity of the proapoptotic gene bax using specific mutations.
• To evaluate the efficacy and safety of a survivin promoter-driven bax mutant (Sur-BaxS184del) vector.

Main Methods:

• Engineered mutants of the proapoptotic gene bax, focusing on mitochondrial translocation and apoptosis induction.
• Utilized the survivin promoter to drive expression of the most active bax mutant (BaxS184del).
• Performed in vitro assays on various tumor cell lines and normal fibroblasts, and in vivo studies using a murine breast cancer model.

Main Results:

• The BaxS184del mutant demonstrated significantly higher apoptotic activity and cancer cell killing efficacy compared to wild-type bax (BaxWT).
• The Sur-BaxS184del vector showed specific tumor cell toxicity with minimal impact on normal human dermal fibroblasts.
• In vivo studies confirmed tumor growth retardation in a mouse model, comparable to CMV-Bax, highlighting targeted efficacy.

Conclusions:

• The BaxS184del mutant, when driven by the survivin promoter, represents a potent and specific agent for tumor-targeted suicide gene therapy.
• This combination offers enhanced efficacy and safety, overcoming limitations of previous suicide gene therapy approaches.
• The study validates the use of engineered bax mutants with tumor-specific promoters in nonviral vectors for cancer treatment.